INSULET CORP
No SEC Form 4 filings for $PODD in the last 30 days.
Insulet reported Q2 2026 results and said U.S. revenue guidance for 2026 was lowered to 20% to 22% growth due to lower-than-expected type 2 retention and utilization, especially in the first 90 days. The company is shifting sales incentives to prioritize retention, investing in Omnipod Discover, expanding customer care, and expects 2026 free cash flow to decline modestly.
US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.
Insulet (NASDAQ:PODD) said execution issues hurt its U.S. Type 2 outlook and outlined steps to improve onboarding, customer support, retention-focused sales incentives, and use of Omnipod Discover. It raised 2026 guidance to 20% to 22% constant-currency total revenue growth and 21% to 23% Omnipod growth, with Q3 growth forecasts. Cash was $535M.
Over the past 7 days, alphai's AI scored 25 news stories mentioning PODD (INSULET CORP). Coverage has skewed bearish: 1 bullish, 8 neutral, and 16 bearish.
Recent PODD coverage spans financial news, earnings and market movers.
Guidance reset tied to type 2 early-therapy attrition and a commercial model shift toward retention, implying near-term margin and growth uncertainty.
PODD’s guidance cut is a high-conviction negative for near-term positioning and sentiment.
Guidance reset centers on Type 2 retention and slower new customer starts, with higher international momentum and continued margin/EPS growth targets.
Guidance cut on the U.S. Omnipod growth line is the key risk, partially offset by margin expansion and higher adjusted EPS outlook.
A guidance cut with a large selloff signals traders are downgrading growth expectations materially.
alphai scores every news story that mentions PODD with an AI model for sentiment and relevance, and aggregates insider trades from INSULET CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Insulet reported Q2 2026 results and said U.S. revenue guidance for 2026 was lowered to 20% to 22% growth due to lower-than-expected type 2 retention and utilization, especially in the first 90 days. The company is shifting sales incentives to prioritize retention, investing in Omnipod Discover, expanding customer care, and expects 2026 free cash flow to decline modestly.
7 min readUS stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.
7 min readInsulet (NASDAQ:PODD) said execution issues hurt its U.S. Type 2 outlook and outlined steps to improve onboarding, customer support, retention-focused sales incentives, and use of Omnipod Discover. It raised 2026 guidance to 20% to 22% constant-currency total revenue growth and 21% to 23% Omnipod growth, with Q3 growth forecasts. Cash was $535M.
4 min readInsulet (NASDAQ:PODD) reported Q2 revenue of $801.7 million, up 23.5%, above guidance. Omnipod revenue rose 24.6%, with U.S. up 20.1% and international up 35.5%. It lowered full-year U.S. Omnipod growth to 17% to 19% from 20% to 22%, and total revenue to 20% to 22%. Adjusted EPS rose 41.5% to $1.66.
4 min readOil prices fell after Axios said the US, Iran and Oman were nearing an interim deal to reopen the Strait of Hormuz. Houthi threats to escalate attacks on Saudi tankers and Trump’s comments added volatility. Bloomberg Intelligence expects Q2 earnings up about 23% and 86% of 387 S&P 500 firms beat estimates. Markets also priced rate-hike odds for the FOMC and ECB.
7 min readStocks rose as strong Q2 earnings expectations supported the S&P 500 hitting a new record high. Bloomberg Intelligence projects Q2 earnings up about 23% and AI spending driving nearly 60% of EPS growth. Of 372 S&P 500 firms reporting, 86% beat estimates, per Bloomberg. The article also cites company movers and rate-hike odds for the FOMC and ECB.
7 min readTD Cowen cut its Insulet price target to $144 from $294, citing a valuation call. The stock was also covered by RBC and Jefferies, with Jefferies adjusting its target to $275 from $360, according to the respective firms. Insulet shares closed at $139.30, up 4.53% on the day.
2 min readRaymond James cut its Insulet price target to $180 from $216, according to the note. Other analysts also adjusted targets, including Jefferies to $275 from $360 and Stifel Nicolaus to $180 from $225. The changes may affect investor expectations for the medical device maker’s outlook.
1 min readRBC Capital lowered its price target on Insulet to $160 from $245 while keeping an Outperform rating, according to the note cited in the article. The piece also mentions other firms adjusting Insulet targets to $275 from $360 (Jefferies) and $180 from $225 (Stifel).
2 min readLeerink Partners downgraded Insulet to Market Perform from Outperform and cut its price target to $145 from $247, according to the firm. The article also notes other broker adjustments to Insulet targets, including Jefferies raising to $275 from $360 and Stifel lowering to $180 from $225.
2 min read